JAMA Oncology
banner
jamaoncology.com
JAMA Oncology
@jamaoncology.com
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

🌐 JAMAOncology.com
From @jama.com: Among #Medicare Advantage beneficiaries aged 75 years or older with #cancer, a lay health worker–administered telephone assessment reduced acute care use, including 68% lower odds of hospitalization, compared with standard care.

ja.ma/4jn7ZVk
December 30, 2025 at 5:30 PM
Both combined and progestin-only contraceptives are linked to increased #BreastCancer risk, with greater risk observed for progestin-only, particularly desogestrel-containing products. ja.ma/3Yjq8cO
December 30, 2025 at 12:00 PM
From @jama.com: After new out-of-pocket caps in 2024, initial and 60-day fill rates increased for #Medicare beneficiaries without low-income subsidies, though affordability barriers remain for specialty oral #anticancer drugs.

ja.ma/4seI0mQ
December 29, 2025 at 5:30 PM
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management. ja.ma/4pZZsdk
December 29, 2025 at 3:00 PM
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. ja.ma/49bnKtv
December 29, 2025 at 1:00 PM
💬 Editorial: Consistent long-term physical activity was linked to optimally reduced risk of digestive system cancers. ja.ma/4avYH6U
December 29, 2025 at 1:00 PM
Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity. ja.ma/4pxFHsJ
December 28, 2025 at 12:00 PM
Immune checkpoint inhibitor–induced #diabetes occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with #chemotherapy. ja.ma/3YQ7tFy
December 27, 2025 at 3:00 PM
A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-stage breast cancer, integrating clinical and treatment variables available at diagnosis. ja.ma/4sdrymH
December 27, 2025 at 1:00 PM
The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for #LungCancer screening, but gains in scan completion were limited. ja.ma/48QffoY
December 26, 2025 at 5:00 PM
Among over 7000 patients with #cancer, higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. ja.ma/4qmZtrt
December 26, 2025 at 4:30 PM
Viewpoint: GLP-1 receptor agonists induce weight loss but may lead to pronounced muscle mass reduction, raising concerns for patients with cancer at risk of frailty and decreased physical function. ja.ma/4qbD8O9
December 26, 2025 at 3:00 PM
During nationwide platinum shortages, #oncologists maintained overall platinum use for nonmetastatic lung cancer and substituted immunotherapy when treating metastatic cases, closely following national guidance. ja.ma/4qiLZwS
December 25, 2025 at 12:00 PM
Viewpoint: The recommendation against hormonal contraception for premenopausal women at risk for or surviving breast cancer while taking tamoxifen is based on limited evidence, underscoring the need for more targeted research. ja.ma/3MPoIEs
December 24, 2025 at 12:00 PM
The numbers are in.

The numbers are in. This year's most popular JAMA Network content spans a range of topics, from #fluoride to #Parkinson disease to #GLP-1s. What was your favorite article in 2025 -- and did other readers agree?

🔗 ja.ma/4sbDfKO
December 23, 2025 at 4:30 PM
Ductal carcinoma in situ (DCIS) score profiling after breast-saving surgery enabled selective radiotherapy, allowing half of women with DCIS to safely avoid radiotherapy while maintaining low 5-year in-breast recurrence rates for all risk groups. ja.ma/498WNXG
December 23, 2025 at 12:00 PM
Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting most survivors benefit from primary care focused on prevention and management of traditional cardiovascular risk factors. ja.ma/4jbyOLW
December 22, 2025 at 1:00 PM
Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions. ja.ma/4pPMpLB
December 22, 2025 at 12:00 PM
Head and neck #cancer is the seventh most common cancer worldwide.

This @jama.com Review summarizes the epidemiology, clinical presentation, diagnosis, and treatment of head and neck squamous cell carcinomas (#HNSCC) of the upper aerodigestive tract.

ja.ma/4pSSyXe
December 21, 2025 at 2:00 PM
Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, with additive effects observed when combined with high-risk drugs. ja.ma/3MMrWIT
December 21, 2025 at 12:00 PM
Heart radiation therapy, high-dose anthracyclines, and platinum agents were linked with increased risk of symptomatic valvular heart disease, especially at higher doses and longer follow-up. ja.ma/4qjS7Fh
December 20, 2025 at 12:00 PM
💬 Viewpoint: Nonfinancial conflicts, including relationships and beliefs, can shape #Oncology research outcomes, highlighting the need for routine disclosure and management to support scientific credibility.

ja.ma/496w0LD
December 19, 2025 at 2:00 PM
Viewpoint: Proposed use of credit screening in clinical settings could enable rapid detection of financial risk at cancer diagnosis, with automated analysis guiding early financial counseling and support. ja.ma/4oYMWJF
December 19, 2025 at 12:00 PM
📢 This Special Communication describes obstacles to sharing data and biospecimens and proposes strategies to enhance access and collaboration.

ja.ma/494xV37
December 18, 2025 at 5:00 PM
Quadrivalent #HPV vaccination was associated with lower rates of high-grade vulvovaginal lesions, especially among women vaccinated at ages 10 to 16, in a large cohort study.

ja.ma/3L9UrQ9
December 18, 2025 at 4:30 PM